Follow the company. Check the evidence.
Public records connected to stocks traded by Congress. See what changed, when it became public, and the original source.
PFE: Department of Defense contract award
4572454271!CEFTRIAXONE 1 GM VIALS
1 congressional household disclosed purchases in the past 90 days. See the trades
PFE: Department of Defense contract award
4572463593!PROTONIX IV 40 MG VIALS
1 congressional household disclosed purchases in the past 90 days. See the trades
PFE: Department of Defense contract award
4572464429!SILVADENE 1% CREAM 20GM
1 congressional household disclosed purchases in the past 90 days. See the trades
PFE: Department of Defense contract award
4572464431!PROVERA 10 MG TABLET 100S
1 congressional household disclosed purchases in the past 90 days. See the trades
PFE: Department of Defense contract award
4572465630!FENTANYL 100 MCG/2 ML VIAL 2ML
1 congressional household disclosed purchases in the past 90 days. See the trades
PFE: Department of Defense contract award
4572465632!SILVADENE 1% CREAM 20GM
1 congressional household disclosed purchases in the past 90 days. See the trades
PFE: Department of Defense contract award
4569621025!CYKLOKAPRON 1,000 MG/10 ML VL 10ML
1 congressional household disclosed purchases in the past 90 days. See the trades
PFE: Department of Defense contract award
4570449896!SOLU-MEDROL 125 MG VIALS
1 congressional household disclosed purchases in the past 90 days. See the trades
PFE: Department of Health and Human Services contract award
PFIZER VACCINES STORAGE AND ROTATION CONTRACT
1 congressional household disclosed purchases in the past 90 days. See the trades
PFE: Department of Defense contract award
COVID-19 VACCINE PRODUCTION
1 congressional household disclosed purchases in the past 90 days. See the trades
PFE: Leadership change
Filed 8-K for an event or period dated 2026-10-30. Leadership change.
1 congressional household disclosed purchases in the past 90 days. See the trades
PFE: 10-Q financial filing
Filed 10-Q for an event or period dated 2026-09-27. Read the company report for its disclosures.
1 congressional household disclosed purchases in the past 90 days. See the trades
PFE: Financial results
Filed 8-K for an event or period dated 2026-11-03. Financial results.
1 congressional household disclosed purchases in the past 90 days. See the trades
PFE: third_quarter 2026 lobbying report
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices. Issues
Public: Oct 20, 2026, 5:49 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
PFE: third_quarter 2026 lobbying report
Issues related to drug pricing Issues related to clinical trial reform Issues related to vaccine policy Issues related to MFN pricing and trade
Public: Oct 20, 2026, 5:38 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
PFE: third_quarter 2026 lobbying report
H.R. 4101 - Cancer Drug Parity Act of 2025 H.R. 5178 - Sickle Cell Disease Comprehensive Care Act S. 3510 - Biosimilar Inspection Modernization Act of 2025 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Codification FDA-2026-N-4699 - Expedited Investigational New Drug (IND) pilot program Section 301 Investigation re: Germany Issues FDA User Fee Agreements: 2027 PDUFA Cycle 340B Program Reform Prior Authorization Vaccine Access and Coverage FDA Modernization and Reforms Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Pl
Public: Oct 20, 2026, 2:54 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
PFE: third_quarter 2026 lobbying report
Medicare and healthcare policy issues as they relate to drug pricing. Issues related to 340B Program General issues with tax reform and foreign tax issues. Issues related to drug consolidation.
Public: Oct 20, 2026, 2:16 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
PFE: third_quarter 2026 lobbying report
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the pharmaceutical industry generally and/or Pfizer specifically.
Public: Oct 20, 2026, 12:37 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
PFE: third_quarter 2026 lobbying report
A lobbying activity report was filed. Income and expenses are separate reporting measures and must not be added together.
Public: Oct 20, 2026, 11:55 AM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
PFE: third_quarter 2026 lobbying report
Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Codification. FDA User Fee Agreements: 2027 PDUFA Cycle. 340B Program Reform. Inflation Reduction Act (IRA). Prior Authorization. Step Therapy Practices. FDA Modernization and Reforms. Drug Pricing. PBM Reform. Vaccine Access and Coverage. Medicare/Medicaid Issues.
Public: Oct 19, 2026, 11:44 AM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
PFE: third_quarter 2026 lobbying report
Issues related to corporate and international taxation. Issues related to OECD Pillar 1 and Pillar 2 negotiations, agreements, implementation, and reporting related to the taxation of global income. Issues related to IRC sections 11, 163(j), 951A, and 250.
Public: Oct 16, 2026, 1:16 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
PFE: third_quarter 2026 lobbying report
A lobbying activity report was filed. Income and expenses are separate reporting measures and must not be added together.
Public: Oct 13, 2026, 10:25 AM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
PFE: first_quarter 2026 lobbying report
Intellectual Property Protections Vaccine Coverage Pediatric Immunization Schedule Vaccine Injury Compensation Program Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 7837 - Most Favored Patient Act of 2026 Lyme Disease Issues 340B Issues Counterfeit Drugs Inflation Reduction Act (IRA) Prescription Drug User Fee Act (PDUFA) Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 3510 - Biosimilar Inspection Modernization Act of 2025 Execu
Public: Oct 7, 2026, 9:27 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
Jeffrey Thies: Final Debarment Order
The Food and Drug Administration (FDA or the Agency) is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) debarring Jeffrey Thies for a period of 10 years from importing or offering for import any drug into the United States. FDA bases this order on a finding that Mr. Thies was convicted of two felony counts under Federal law for trafficking in counterfeit goods and aiding and abetting. The factual basis supporting Mr. Thies's conviction, as described below, is conduct relating to the importation into the United States of a drug or controlled substance. Mr. Thies was given notice of the proposed debarment and was given an opportunity to request a hearing to show why he should not be debarred. As of July 13, 2026 (more than 30 days after receipt of the notice), Mr. Thies had not responded. Mr. Thies's failure to respond and request a hearing constitutes a waiver of his right to a hearing concerning this matter.
Public: Sep 25, 2026Original source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
Advisory Committee; Oncologic Drugs Advisory Committee; Renewal
The Food and Drug Administration (FDA) is announcing the renewal of the Oncologic Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Oncologic Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the September 1, 2028, expiration date.
Public: Aug 21, 2026Original source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
Connections describe public records, not evidence of wrongdoing or a prediction of returns. Event dates can precede publication by days or months. When a source has no public-release timestamp, we show when we first observed it.
Source coverage
Coverage is growing across companies already tracked here. A scan can return no matching records. This feed is not a complete record of every filing or agency action.
- SEC EDGAR
- Current across tracked companies505 of 505 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 3:27 PM EST
- USAspending
- Collection in progress57 of 548 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 3:27 PM EST
- SAM.gov
- Awaiting company connections
- Lobbying disclosures
- Not yet scanned0 of 548 companies scanned in the past 12 hours
- Congress.gov
- Current across tracked companies5 of 5 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 2:39 PM EST
- Federal Register
- Stale — refresh overdue297 of 548 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 3:27 PM EST
- Regulations.gov
- Collection in progress30 of 53 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 3:00 PM EST
- FEC campaign finance
- Stale — refresh overdue0 of 548 companies scanned in the past 12 hoursLatest successful company scan: Nov 11, 2026, 1:28 PM EST